Last reviewed · How we verify
Glyburide-Metformin combination
At a glance
| Generic name | Glyburide-Metformin combination |
|---|---|
| Sponsor | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Headache
- Dizziness
- Hyperhidrosis
- Hunger
- Tremor
Key clinical trials
- Durability of Combination Therapy With Exenatide/Pioglitazone/Metformin vs. Conventional Therapy in New Onset T2DM (PHASE4)
- Comparative Analysis of Cost-effectiveness Between Sulfonylureas and DPP4 Inhibitors in Combination With Metformin in Treatment of Type 2 Diabetic Patients : A Retrospective, Observational Study.
- Glycaemic & Cardiovascular Treatment Outcomes of Voglibose Vs Glibenclamide Added to Metformin in T2DM Patients (PHASE3)
- Study of Sitagliptin Treatment in Patients With Type 2 Diabetes During Ramadan (0431-263) (PHASE4)
- Glyburide vs Glucovance in the Treatment of GDM (EARLY_PHASE1)
- Metformin in Patients With Fragile X (PHASE1, PHASE2)
- Gestational Diabetes: Insulin or Oral Hypoglycemic Agents? (PHASE3)
- RECORD: Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: